Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | unknown | Phase 2 / Phase 3 | 298 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02504983 | Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma | unknown | Phase 4 | 200 | Chang Gung Memorial HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03969576 | Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC) | unknown | N/A | 344 | Air Force Military Medical University, ChinaOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04239781 | A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular Carcinoma | unknown | — | 2,500 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04241523 | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04243057 | Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study | unknown | — | 5,000 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03211598 | Surefire Institutional DEB-TACE | unknown | N/A | 15 | Alexander KimOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04220151 | Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C | unknown | — | 100 | Assiut UniversityOTHER | 0 | Jan 14, 2020 | clinicaltrials |
| NCT04227808 | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04221347 | Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC | unknown | — | 250 | Military University Hospital, PragueOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02436902 | Adjuvant Therapies for Patients With HCC and MVI(A-TACE/S-HCC) | unknown | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04193696 | RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) | unknown | Phase 2 | 39 | Guangxi Medical UniversityOTHER | 0 | Jan 9, 2020 | clinicaltrials |
| NCT04209491 | Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway(INFIC) | unknown | — | 1,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04215861 | Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy | unknown | — | 1,000 | The First Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04206254 | GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer | unknown | Phase 2 / Phase 3 | 80 | Cure&Sure Biotech Co., LTDINDUSTRY | 0 | Dec 20, 2019 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT04202523 | Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma | unknown | Phase 3 | 50 | Guangxi Medical UniversityOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03771846 | HAIC Versus Systemic Chemotherapy for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT03851913 | The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy | unknown | Phase 3 | 344 | Sun Yat-sen UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT03774589 | Bilioenteric Anastomosis by Magnetic Compressive Technique(BAMCT) | unknown | N/A | 200 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03792048 | Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure | unknown | N/A | 50 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04163237 | Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer | unknown | Phase 3 | 50 | Guangxi Medical UniversityOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04160897 | Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis | unknown | — | 4,000 | Qing XIeOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04158414 | Applying PET/MR in Oncology - a Prospective Project | unknown | N/A | 500 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 8, 2019 | clinicaltrials |
| NCT04152356 | Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma | unknown | — | 50 | Guangxi Medical UniversityOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT03790059 | Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma. | unknown | N/A | 160 | Southwest Hospital, ChinaOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)(PIPACRegis) | unknown | — | 1,000 | Sabine RhodeOTHER | 13 | Oct 8, 2019 | clinicaltrials |
| NCT04111380 | Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers | unknown | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01825824 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm | unknown | Phase 2 | 54 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04006275 | Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC | unknown | Phase 3 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01451658 | A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC) | unknown | Phase 4 | 100 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04077983 | Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 4, 2019 | clinicaltrials |
| NCT01970748 | Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices(P-HCC) | unknown | Phase 4 | 200 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03042182 | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma(cholangio) | unknown | Phase 1 / Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03993743 | A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 34 | Xijing HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02733809 | Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 4 | 40 | King Saud UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03905967 | TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC(TACE) | unknown | Phase 3 | 336 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT04053972 | The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | unknown | Phase 3 | 377 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 13, 2020source: clinicaltrials